ALKS

Alkermes Plc. 10-Q Summary: Q2 2026

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Alkermes Plc. is a global biopharmaceutical company focused on neuroscience. The reporting period is defined by the completion of the Avadel Pharmaceuticals plc acquisition on February 12, 2026. This transaction added the narcolepsy treatment LUMRYZ to Alkermes' proprietary portfolio and integrated a commercial organization experienced in sleep medicine. The company operates as a single segment.

Key Financial Metrics

Liquidity: Total cash, cash equivalents, and investments stood at $691.6 million as of June 30, 2026. The company generated $1.51 billion in net proceeds from debt financing during the six months ended June 30, 2026, primarily to fund the Avadel acquisition.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by 27% in Q2 2026 and 27% YTD 2026 compared to the prior year periods. This growth was driven primarily by the inclusion of LUMRYZ sales ($96.6 million in Q2; $136.1 million YTD) and an 18% increase in LYBALVI unit sales.
• Profitability Decline: Net income decreased significantly due to the Avadel acquisition. Operating expenses rose by $180.0 million in Q2 and $328.5 million YTD. Key drivers included:
  • Amortization: $22.6 million (Q2) and $34.3 million (YTD) related to acquired intangible assets (LUMRYZ).
  • Contingent Consideration: A $26.4 million expense recognized due to an increased probability of achieving the CVR Milestone following positive Phase 3 results for LUMRYZ in idiopathic hypersomnia.
  • Interest Expense: $25.9 million (Q2) and $46.8 million (YTD) resulting from new term loan facilities ($1.525 billion total) entered into to finance the acquisition.
• Balance Sheet Impact: Total assets increased from $2.49 billion to $4.39 billion. Goodwill increased by $511.2 million to $594.3 million, and intangible assets increased by $1.76 billion due to the acquisition.

Guidance, Outlook, and Risks

• Outlook: Management expects existing cash and investments to be sufficient to finance operations for at least the next 12 months. The company is advancing the Alixorexton Phase 3 program (Brilliance Studies) for narcolepsy.
• Contingent Consideration: The company holds a liability of $136.3 million for potential milestone payments to former Avadel shareholders. This liability is subject to revaluation based on clinical trial outcomes and probability of success.
• Legal Proceedings:
  • LYBALVI Litigation: Patent infringement lawsuits filed against Teva, Apotex, and MSN regarding generic ANDA filings. These triggered 30-month stays on FDA approval for the generics.
  • VIVITROL Antitrust: A class action lawsuit alleging fraudulent patent listing and enforcement, seeking unspecified damages.
  • Acorda Appeal: The Second Circuit affirmed a decision in favor of Alkermes regarding an arbitration award dispute in July 2026.
• Debt Covenants: The company is in compliance with debt covenants as of June 30, 2026, including maximum Secured Net Leverage Ratio and minimum Consolidated Interest Coverage Ratio.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline for realizing synergies from the Avadel acquisition and the commercial performance of LUMRYZ post-acquisition.
• Debt Service Capacity: Assess the impact of the new $1.525 billion debt load on future cash flows, specifically the ability to meet interest payments and principal amortization.
• Contingent Liability Volatility: Monitor the fair value of the $136.3 million contingent consideration, which fluctuates based on clinical trial probabilities (currently 90% for the CVR Milestone).
• Patent Litigation Status: Track the progress of the LYBALVI and VIVITROL litigation, as adverse outcomes could threaten revenue streams from these key products.
• Amortization Schedule: Review the projected amortization of the $1.76 billion in acquired intangible assets, which is expected to be approximately $79.9 million for the remainder of 2026.